No Data
Optimistic outlook for cancer and inflammation drugs has led novartis ag (NVS.US) to raise mid-term sales expectations.
Based on optimistic expectations for new drugs for cancer and immune diseases, as well as treatments for neurological and cardiovascular diseases, novartis ag has raised its mid-term sales forecast.
Novartis Pipeline Catalysts On Track, Cancer Drugs in Focus -- Market Talk
Goldman Sachs Sticks to Its Hold Rating for Novartis AG (NOVN)
Cautious Optimism: Balancing Novartis AG's Growth Projections With Market Skepticism and Patent Risks
Novartis's Midterm Guidance Lift Tops Consensus View -- Market Talk
Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)
No Data
No Data
